RxDoctor Payments Data

Ughanmwan Efeovbokhan, NP

Gerontology · Windcrest, TXNPI 1649387630

Payments from drug & device makers

$3,118in general payments, 2019–2025

Across 138 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$476
  • Avanir Pharmaceuticals, Inc.$398
  • Vanda Pharmaceuticals Inc.$242
  • Amgen$234
  • Lilly USA, LLC$206
  • plus $558 from 10 others

What the payments were for

  • Food & beverage$3,117100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,118 in reported general payments places this provider in the 85th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$161,548
Medicare patients
67
Services billed
8,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide188$209,098
Invega SustennaPaliperidone Palmitate38$130,462
Metformin Er GastricMetformin Hcl27$32,027
OzempicSemaglutide22$20,087
JanuviaSitagliptin Phosphate18$19,221
JardianceEmpagliflozin16$14,717
FarxigaDapagliflozin Propanediol11$11,739
EliquisApixaban17$10,129
LinzessLinaclotide16$8,331
XareltoRivaroxaban14$7,855
Dexlansoprazole DrDexlansoprazole16$3,749
Alprazolam359$3,391
Paliperidone ErPaliperidone18$2,736
Acetaminophen-CodeineAcetaminophen With Codeine244$2,605
Lubiprostone24$2,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Olanzapine$206$209,686209 claims
Johnson & JohnsonInvega Sustenna, Xarelto$49$138,31652 claims
AstraZenecaFarxiga$15$11,73911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 653 gerontology providers in Texas.

Other gerontology in Windcrest

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →